Positive phase III data gives Merck potential boost for blockbuster Keytruda in injection form

Positive phase III data gives Merck potential boost for blockbuster Keytruda in injection form
Merck's Keytruda cancer drug shows promise in injection form, potentially expanding treatment options. Analysts predict mixed impact on Merck's revenue due to patent expiration and pricing differences between injection and IV forms. FDA decision on approval expected by September 23.